Google
×
Sartans are used to treat patients with hypertension (high blood pressure) and those with certain heart or kidney diseases. They work by blocking the action of ...
... sartans'. There is a very low risk that nitrosamine impurities at the levels found in medicines could cause cancer in humans. Scientific review on the risk ...
People also ask
This decision was based on the scientific assessment of angiotensin-II-receptor antagonists (sartans) ... The five sartans ... EMA · HMA · WHO. CONTACT US. Press ...
Nov 28, 2020 · The European Medicines Agency (EMA) has aligned its recommendations on limiting nitrosamine impurities in sartans (angiotensin II receptor ...
Angiotensin receptor blockers (ARBs) or the 'sartans' are widely used for the management of hypertension and heart failure. ... https://www.ema.europa.eu/en/news/ ...
Jan 3, 2023 · EMA 's human medicines committee ( CHMP ) has aligned recommendations for limiting nitrosamine impurities in sartan medicines with recent ...
... sartan' blood pressure medicines to: ... These requirements align with those being applied by the European Medicines Agency (EMA). ... (sartans) containing a ...
The main change concerns the limits for nitrosamines, which will now apply to the finished products (e.g. tablets). These limits, should ensure that excess risk ...
According to the EMA report on angiotensin II receptor antagonists (sartans) containing a tetrazole group, impurities can form during the production of sartans ...
Mar 24, 2021 · In a final assessment report, the EMA has ... (sartans) regarding nitrosamine contamination limits and deadlines for risk mitigation measures.